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ABSTRACT
This study was designed to determine the effect of immunotoxin HuM195/rGel on normal human bone
marrow before clinical purging. HuM195/rGel is composed of the recombinant plant toxin gelonin (rGel)
chemically coupled to the anti-CD33 human chimeric antibody HuM195. The CD33 antigen is of significant
interest as a target for therapy of acute myelogenous leukemia because it is present in leukemic blasts of most
patients but absent in the earliest progenitor bone marrow cells. HuM195/rGel was optimally cytotoxic to
acute myelogenous leukemia HL60 cells with 24 hours of exposure. We developed an in vivo purging model
by mixing mobilized peripheral blood progenitor cells with HL60 cells to simulate a remission in bone marrow.
Cells were treated with 10 nmol/L of HuM195/rGel either with or without exposure to freeze/thaw procedure,
which has been reported to act synergistically with HuM195/rGel to produce cytotoxic effect. When clono-
genic cell recovery rates were determined, HuM195/rGel alone did not affect normal peripheral blood
progenitor cells, whereas HuM195/rGel plus freeze/thaw provided 2 logs of tumor cell elimination in our
purging model. We also observed similar results under conditions used in the transplantation setting. We
concluded that for acute myelogenous leukemia blasts expressing CD33, HuM195/rGel could be useful as a
purging reagent for autologous transplantation.
© 2003 American Society for Blood and Marrow Transplantation
KEY WORDS
HuM195/rGel ● Acute myelogenous leukemia (AML) ● CD33 antigen ● Anti-CD33
immunotoxin ● Bone marrow purging
INTRODUCTION
Acute myelogenous leukemia (AML), primarily a
disease of the bone marrow, is deﬁned as the clonal
expansion of malignant myeloid cells blocked in de-
velopment [1]. Conventional treatment of AML is a
combination of chemotherapeutic agents, resulting in
remission rates of 60% to 80% [2]. However, patients
with AML are prone to relapse, with a median survival
time of approximately 18 months if they are not
treated with bone marrow transplantation (BMT).
Following relapse, further chemotherapy can re-es-
tablish complete remission in approximately 40% of
patients, but such remissions tend to be short, aver-
aging 3 to 6 months [2].
Allogeneic BMT has been shown to signiﬁcantly
reduce relapse rates in patients with AML in their ﬁrst
complete remission [3]. However, because of signiﬁ-
cant treatment-related mortality, the overall disease-
free survival rate is approximately 50% at 5 years [3].
In a patient’s second and third complete remissions,
allogeneic BMT results in a relapse-free survival rate
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of 20% to 30% at 5 years. The outcome of patients
with more advanced disease is worse because of higher
relapse rates and higher treatment-related toxicity [4].
A major limitation of allogeneic BMT is that it can
be applied only to a subset of patients with AML: Only
about 40% of patients have HLA-matched donors,
and most patients older than 55 years are considered
too old to tolerate the procedure. Studies of allogeneic
BMT with matched, unrelated donors have shown
that advanced disease, old age, and high degrees of
HLA disparity are associated with a poor outcome
because of excessive morbidity and mortality of graft-
versus-host disease [3]. Therefore, alternative treat-
ment strategies are necessary for most patients with
AML [4].
Autologous BMT, a promising alternative for the
treatment of AML, has several advantages over allo-
geneic BMT: it does not preclude treatment because
of the lack of a bone marrow donor, it can be used in
patients up to 65 years old, and it is not associated with
graft-versus-host disease. There is concern that the
relapse rate with autologous BMT will be higher than
that with allogeneic BMT because of the potential
reinfusion of bone marrow that is contaminated with
clonogenic leukemia cells and because of the absence
of a graft-versus-leukemia effect [4]. However, nu-
merous studies have shown that the outcomes of au-
tologous BMT are favorable when compared with
those of allogeneic BMT [5-12].
To increase the efﬁcacy of autologous BMT,
methods of purging bone marrow using monoclonal
antibodies (MoAbs) or cytotoxic drugs have been used
[13-18]. The pharmacologic agents that have been
used for ex vivo purging of tumor cells include 4-
hydroxyperoxycyclophosphamide, mafosfamide, and
etoposide [13,16,19-21]. These agents impair prompt
engraftment of normal hematopoietic progenitor cells
[22].
Hematologic malignancies are ideal model sys-
tems for the application of antibody-based therapies
because they have very distinguished cell lineages and
stages of differentiation. Furthermore, patients with
these malignancies have readily accessible neoplastic
cells in the blood, marrow, spleen, and lymph nodes
that allow rapid and efﬁcient targeting of speciﬁc
antibodies [23]. The immunotoxin HuM195/rGel,
which consists of a humanized anti-CD33 MoAb con-
jugated to the single-chain plant toxin gelonin (rGel),
is another potential agent for purging. Binding of the
immunotoxin to hematopoietic cells that express the
CD33 antigen produces cytotoxicity caused by ribo-
somal inactivation by gelonin [24-27]. The CD33 an-
tigen is highly restricted to early, committed erythroid
or myelomonocytic progenitors and a subset of mono-
cytes and is present in most acute and chronic myeloid
and monocytic leukemias. Because it is not expressed
on the earliest normal hematopoetic cells, this antigen
is highly unique for purging leukemic blasts from
bone marrow of patients who have CD33-positive
malignancies [28].
In this report, we asked whether HuM195/rGel
could be used as a purging agent by developing an in
vitro model to test its speciﬁc toxicity against leukemic
blasts and its effect on normal progenitor cells of bone
marrow. To increase the toxicity on blast cells, we
combined HuM195/rGel with a freeze/thaw (F/T)
procedure, which is known to have synergistic anti-
leukemic effect [29]. This combination is able to elim-
inate 2 logs of tumor cells and allow 60% of peripheral
blood progenitor cells (PBPCs) survive [30]. Results of
ﬂow cytometry and colony formation assays showed
that HuM195/rGel can be used as an effective and safe
purging reagent.
MATERIALS AND METHODS
Preparation of Immunotoxin
HuM195, a humanized anti-CD33 MoAb gener-
ously supplied by Protein Design Labs Inc. (Mountain
View, CA) was prepared as previously described [24].
rGel was expressed in Escherichia coli and puriﬁed
according to a previous protocol [27]. Brieﬂy, N-
succinimidyl 3-(2-pyridylthio) propionate-modiﬁed
HuM195 in 100 mmol/L sodium phosphate buffer
and 0.5 mmol/L EDTA (pH 7.0) was mixed with a 5
mol/L excess of 2-iminothiolane-modiﬁed rGel. The
pH was adjusted to 7.0 with 0.5 mol/L triethanol-
amine hydrochloride (pH 8.0), and the mixture was
incubated for 20 hours at 4°C under nitrogen. To stop
the reaction, iodoacetamide was added to a ﬁnal con-
centration of 2 mmol/L. The reaction mixture was
then incubated for 1 hour at room temperature and
was puriﬁed on a Sephacryl (Amersham Biosciences
Inc, Piscataway, NJ) S-300 gel ﬁltration column equil-
ibrated with 20 mmol/L Tris and 50 mmol/L NaCl
(pH 7.4). The fractions containing HuM195/rGel and
unreacted antibody were pooled and loaded onto a
Cibacron blue-Sepharose CL-6B column equilibrated
with Tris buffer to remove the unconjugated anti-
body. Puriﬁed immunotoxin was eluted with 20
mmol/L Tris/2 mol/L NaCl buffer (pH 7.4) and di-
alyzed against phosphate-buffered saline (PBS) [29].
Peripheral Blood Progenitor Cells (PBPCs)
After informed consent was obtained, PBPCs were
collected from granulocyte colony-stimulating factor-
mobilized healthy donors using the Spectra Apheresis
device (Gambro BCT, Inc., Lakewood, CA) at the
University of Texas M. D. Anderson Cancer Center
(Houston , TX). Samples were immediately processed,
and mononuclear cells were isolated by Ficoll-
Hypaque density gradient centrifugation (Hypaque
1077 was purchased from Sigma Chemical Co., St.
Bone Marrow Purging in AML with HuM195/rGel
365BB&MT
Louis, MO). The percentages of CD34-positive cells
in these samples ranged from 0.4% to 1.7%. For
upscaled experiments, whole PBPC samples from 8
healthy donors and 5 leukemia patients were used
without isolation of mononuclear cells. All cell cul-
tures except the upscaled whole PBPC samples were
maintained in -minimal essential medium (-MEM;
Life Technologies, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS; Life Technolo-
gies) at 37°C with 5% CO2 in a humidiﬁed chamber.
Leukemic Cells
The human promyelocytic leukemia HL60 cell
line was used to model human leukemia in which
more than 85% of leukemic human blasts expressed
the CD33 antigen. Fresh leukemic blasts from periph-
eral blood of a patient with accelerated-phase chronic
myeloid leukemia were isolated using Ficoll-Hypaque
density gradient centrifugation.
Clonogenic Cultures
Two different clonogenic cultures were prepared
for the small-scale experiments: One contained only
normal PBPCs (1 106/mL), and the other contained
normal PBPCs and human leukemic HL60 cells in a
9:1 ratio (1  106 cells/mL) to simulate bone marrow
contaminated with 10% leukemic blasts. All cells were
incubated in liquid culture for 24 hours with 1 nmol/L
or 10 nmol/L HuM195/rGel. After incubation, cells
were washed twice in Hank’s Balanced Salt Solution
(HBSS) without calcium or magnesium (Biowhittaker,
Walkersville, MD) and plated as described below. For
the F/T procedure, washed cells were resuspended in
1 mL of freezing medium (10% dimethylsulfoxide
(DMSO), 40% -MEM, and 50% FBS) and kept in a
70°C freezer in 1.5 mL cryotubes for 24 hours. Cells
were then quickly thawed in a 37°C water bath and
added to 6-mL tubes containing 4 mL of prewarmed
-MEM supplemented with 10% FBS. After 2 hours
of incubation at 37°C with 5% CO2, cells were cen-
trifuged and fresh medium was added. The cells were
then incubated for another 24 hours, collected, and
resuspended in fresh medium, and plated as described
below.
Plating Procedure for Peripheral Blood Progenitor
Cells
Cells washed with HBSS were resuspended in
semisolid medium containing recombinant cytokines
(MethoCult GF H4434; Stem Cell Technologies,
Vancouver, BC) including 1% methlycellulose in
Iscove’s modiﬁed Dulbecco’s medium, 30% FBS, 1%
bovine serum albumin, 104M 2-mercaptoethanol, 2
mmol/L L-glutamine, 50 ng/mL recombinant human
stem cell factor, 10 ng/mL rh granulocyte-macro-
phage colony-stimulating factor, 10 ng/m rh IL-3, and
3 U/mL rh erythropoietin. Cells were then plated in
quadruplicate in 96-well microtiter plates (Linbro/
Titertek; ICN Biomedicals, Aurora, OH) at a density
of 4  104 cells/0.1 mL. Aggregates of more than 50
cells were counted as 1 colony using an inverted light
microscope (hundWetzlar; Germany) after 7 to 9 days
of incubation at 37°C in a 5% CO2 humidiﬁed cham-
ber. Growth inhibition was evaluated as the percent-
age of colony growth compared with colony growth in
untreated (control) samples.
Plating Procedure for Mixture of Peripheral Blood
Progenitor Cells and HL60 Cells
Plating medium (-MEM with 15% FBS and
0.8% methylcellulose in -MEM) that did not include
essential growth factors required for colony formation
of PBPCs was used to establish HL60 cell-only colo-
nies. Cells were resuspended in semisolid medium and
plated in quadruplicate for HL60 2 102 cells/0.1 mL
in 96-well microtiter plates. The amount of plating
medium was equal to the cell suspension volume.
Colonies consisting of more than 20 HL60 cells were
counted after 4 to 6 days of incubation at 37°C in a 5%
CO2 humidiﬁed chamber.
Development of Clinical-Scale Ex Vivo Purging
Conditions
Pheresis samples obtained from 8 healthy donors
or white blood cell depletion samples obtained from 5
leukemia patients were subcultured in T75 ﬂasks at a
density of 2  107/mL in RPMI-1640 medium (Life
Technologies) supplemented with 10% human plasma
with the same blood type as the sample (obtained from
the Blood Bank at M. D. Anderson Cancer Center),
0.25% heparin (20 000 USP units/mL) purchased
from Wyeth Laboratories Inc. (Philadelphia, PA),
0.1% gentamicin sulfate (50 mg/mL) (Biowhittaker),
and 1% L-glutamin (Sigma). Cells were untreated or
treated with 50 nmol/L HuM195/rGel for 24 hours
and incubated at 37°C in a 5% CO2 humidiﬁed cham-
ber. Next, cells were collected and resuspended in 2
mL of HBSS supplemented with 5% human serum
albumin (Baxter; Glendale, CA). The total cell volume
was adjusted to 5 mL using a freezing medium that
contained 10% DMSO and 20% human serum albu-
min in HBSS. Cell suspensions were then frozen at
150°C using a controlled-rate freezer. Freezing time
ranged from 3 days to 1 year. Cells were then quickly
thawed in a 37°C water bath and PBS (Life Technol-
ogies) with 50 U/mL Bensonase was added to prevent
cell clumping. The volume of PBS was 10 times
higher than that of the frozen sample to dilute the
DMSO and to avoid its cytotoxicity. Samples were
immediately evaluated for their total absolute CD34-
positive cell counts using ﬂow cytometry and for their
colony formation ability using highly sensitive colony
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formation assay. Cells in upscaled samples were plated
at densities of 5  104cells/mL, 1  105cells/mL, and
2  105cells/mL and counted using an inverted mi-
croscope after a 14-day incubation at 37°C in a 5%
CO2 humidiﬁed chamber.
Internalization Studies of HuM195/rGel by Flow
Cytometry
Fluorescein isothiocyanate (FITC)-labeled goat
anti-human IgG F(ab)2 antibody fragments (GAH-
FITC) were purchased from Caltag (Burlingame,
CA). Mouse anti-CD33 phycoerythrin, mouse anti-
IgG FITC, mouse anti-IgG phycoerythrin, anti-
CD34 FITC, FACS lysing solution, and FACS per-
meabilizing solution were obtained from Becton
Dickinson Immunocytometry Systems (San Jose, CA).
7-Amino-actinomycin D nucleic acid dye was pur-
chased from Pharmingen (San Diego, CA). All analy-
ses were performed using a FACScan (Becton Dick-
inson).
To determine the binding of humanized anti-
CD33 MoAb HuM195 and HuM195/rGel to CD33
antigen receptors, cells were preincubated with or
without HuM195/rGel for 30 minutes at room tem-
perature to allow binding. Cells were then collected
and those that were not exposed to HuM195/rGel
were incubated with HuM195 for 20 minutes at room
temperature. Next, they were exposed to mouse anti-
CD33 MoAb phycoerythrin to determine the extent
of blockage of CD33 receptors.
Determination of Hum195/rGel Internalization by
Immunofluorescence
HL60 cells (1  106 cells/mL) were incubated
with 1 nmol/L HuM195/rGel at 37°C in different
time periods (1 minute, 5 minutes, 30 minutes, 1 hour,
4 hours, and 24 hours). Cell-surface bound Hum195/
rGel was stripped using 200 L glycine buffer (500
mmol/L NaCl, 0.1 mol/L glycine, pH 2.5) in the cold
and neutralized with 0.5 mol/L Tris, pH 7.4. Cells in
suspension were ﬁrst attached to the slides by cyto-
spin. They were then ﬁxed with cold acetone for 5
minutes at 20°C, and washed with PBS containing
0.2% Triton100 at room temperature. Afterwards,
the cells were blocked by incubation in 5% normal
goat serum in PBS for 1 hour. We added 5 g anti-
rabbit rGel antibody, and slides were further incu-
bated at 4°C overnight. Cells were washed with PBS
for 15 minutes and incubated with FITC-labeled anti-
rabbit IgG for 1 hour in the dark. Drug internalization
in the cell cytoplasm was detected by ﬂuorescence
microscopy.
Upscaled samples were evaluated for their total
absolute CD34- and CD33-positive cell numbers. Pe-
ripheral blood progenitor cells were untreated or
treated with HuM195/rGel, frozen, thawed, and im-
mediately assessed for their absolute CD34-positive
cell numbers by staining with an anti-CD34 MoAb.
Nonviable cells were excluded using 7-amino-actino-
mycin D, which can be used in conjunction with
FITC-labeled MoAbs in 2-color analysis. Cells were
counted using Coulter counter (Becton Dickinson).
Total absolute CD34-positive cell numbers were
compared between 8 treated or untreated normal do-
nor samples using the Wilcoxon signed rank test.
Cells from 8 normal donors and 5 patients with AML
were stained with anti-CD33 antibody to demonstrate
blockage of CD33 antigen sites.
RESULTS
Inhibition of colony formation in HL60 cells was
found to be both time- and dose-dependent (Figure
1). Minimal contact time to achieve optimal biological
effect occurred between 4 and 16 hours of exposure
and with as little as 5 nmol/L exposure to the immu-
notoxin. Exposure to 50 nmol/L HuM195/rGel elim-
inated 2 logs of tumor cells after 16 hours of incuba-
tion. Treatment of cells with various doses of
immunotoxin above approximately 10 nmol/L re-
sulted in little increase in cytotoxicity, especially when
cells were treated with immunotoxin for more than 16
hours. Our next studies examined antigen saturation at
various doses. All CD33 receptors were blocked 100%
by 10 nmol/L, 25 nmol/L, and 50 nmol/L HuM195
Figure 1. Time-course studies to determine optimal exposure du-
ration and concentration of HuM195/rGel to provide maximal
toxicity on HL60 cells. Log-phase cells were treated with various
concentrations of HuM195/rGel and the cells were exposed for
indicated times. After immunotoxin administration, cells were
plated quadruplicate to determine colony number. Mean colony
numbers are shown with 95% conﬁdence intervals. Optimal expo-
sure duration was approximately 24 hours and treatment with 5 to
10 nmol/L HuM195/rGel appeared to be a dose range for optimal
biological effect.
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and with or without identical concentrations of
HuM195/rGel, as veriﬁed by using mouse anti-CD33
MoAb as a competitor (data not shown). This result
conﬁrms the dose-response data (Figure 1) showing
that doses above 10 nmol/L were not more cytotoxic
and that receptor saturation occurs at doses of 10
nmol/L and below.
To examine internalization events, which are re-
quired for development of cytotoxic effects of the rGel
toxin, we next examined intracellular concentrations
of the rGel component of the immunotoxin on HL60
cells at various times after treatment with the con-
struct using immunoﬂuorescence. As shown in Figure
2, within 4 hours after treatment, large numbers of
cells were found to contain concentrations of rGel in
the cytoplasmic compartment. The levels of rGel in
treated cells reached maximal levels within 24 hours
and remained constant thereafter. Our ﬁnding was
consistent with previous data that established that
CD33 modulation and internalization begins within
minutes of binding in vitro and in vivo [31-35].
We next examined leukemic blast isolates from a
patient with CML accelerated phase. These cells were
treated with either HuM195/rGel alone or the immu-
notoxin plus a F/T procedure that we had previously
shown to act synergistically with immunotoxin treat-
ment [29,30]. Leukemic blast cells showed some sen-
sitivity to HuM195/rGel alone and addition of the
F/T allowed 90% toxicity with a dose of 25 nmol/L of
the immunotoxin (Figure 3).
Peripheral blood progenitor cells were not af-
fected by 1 nmol/L or 10 nmol/L HuM195/rGel
treatment alone (Figure 4). The F/T procedure alone
or in combination with HuM195/rGel, however, had
some negative effects on the clonogenic recovery of
PBPCs. The PBPCs showed an approximately 60%
recovery rate after F/T or HuM195/rGel plus F/T,
and the absence of any signiﬁcant difference between
the 2 conditions (F/T alone and HuM195/rGel plus
F/T) indicated that the toxicity may have originated
from the F/T procedure alone.
Clinical-scale purging samples were then evalu-
ated for total absolute CD34- and CD33-positive cell
numbers. No statistically signiﬁcant cytotoxic effect
was observed on CD34-positive normal donor PBPCs
Figure 2. Internalization of HuM195/rGel on HL60 cells at various times as assessed by immunoﬂuorescence microscopy. Cells were treated
at various times with immunotoxin, washed and cell-surface bound immunotoxin was removed using an acid wash. The cells were then
permeabilized and stained with anti-rGel polyclonal antibodies. As shown, cytosolic levels of the rGel toxin can be observed as early as 30
minutes after treatment. Fluorescence intensity and cell staining was maximal from 4 to 24 hours after treatment.
Figure 3. Dose-response curve for a patient with accelerated-phase
CML without (wo) or with (w) the F/T procedure. A leukemic blast
isolate from a CML patient was treated with various concentrations
of HuM195/rGel and subjected to freeze-thaw procedure (F/T).
The number of colonies was then determined. As shown, the F/T
procedure increased the cytotoxic effect of the immunotoxin by
approximately 50% at all doses tested.
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treated with HuM195/rGel alone, F/T alone, or
HuM195/rGel followed by F/T (Figure 5). Absolute
CD33-positive cell number was reduced signiﬁcantly
in all samples, indicating complete CD33 antigen re-
ceptor occupation by the immunotoxin (data not
shown). Freezing time, which ranged from 3 days to 1
year, did not have signiﬁcant effect on total cell yield
and viability.
Clonogenic assay in clinical-scale purging samples
has shown that the number of colonies formed by
PBPCs treated with 50 nmol/L HuM195/rGel was
not signiﬁcantly different from that formed by un-
treated PBPCs (Figure 6). Cells that underwent F/T
alone or F/T plus immunotoxin treatment formed
moderately fewer colonies than did cells treated with
immunotoxin alone.
Finally, HL60 cells were mixed with PBPCs to
simulate a remission in bone marrow. The combina-
tion of 10 nmol/L immunotoxin treatment and the
F/T procedure caused a 2-log decrease in colonies
formed by HL60 cells (Figure 7).
DISCUSSION
In this report, we (1) determined the effect of a
recently developed anti-CD33 immunotoxin, HuM195/
Figure 4. Number of colonies formed by PBPCs treated with
HuM195/rGel without (wo) or with (w) the F/T procedure. Each
bar represents a median of 9 normal donor samples and includes
standard error bars. As shown, the effect of the immunotoxin on
normal donor colonies was minimal with or without subjecting cells
to F/T.
Figure 5. Solid bars represent absolute CD34-positive cell numbers
under different treatment conditions using clinical scale procedures.
Mean values (with standard error bars) from 10 PBPC samples are
shown. PBPCs showed a reduction in number when subjected to
F/T; however, treatment with the HuM195/rGel immunotoxin
alone had no effect, nor did the immunotoxin increase the cell
reduction caused by the F/T procedure.
Figure 6. Colony formation of PBPCs from normal donors using
clinical scale conditions. Mean values (with standard error bars) of
5 samples are shown. F/T, freeze/thaw; IT, immunotoxin.
Figure 7. Number of colonies formed by HL60 cells after prepar-
ing a mixture of PBPCs and HL60 cells (at a 9:1 ratio) and treating
with HuM195/rGel without (wo) or with (w) subsequent F/T pro-
cedure. Each bar represents a median (with standard error bars) of
9 normal donor samples mixed with HL60 cells. Colonies are
formed only by HL60 cells. As this ﬁgure demonstrates, addition of
as little as 1 nmol/L of the HuM195/rGel immunotoxin markedly
impacts the HL60 colony number and combination of immuno-
toxin and F/T results in a 10-fold reduction in the colony-forming
ability of HL60 cells.
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rGel, on normal bone marrow cells, and (2) used an in
vitro model in which PBPCs were mixed with AML
HL60 cells to determine the efﬁcacy of HuM195/rGel
with or without an F/T procedure in purging leukemic
cells from bone marrow. Our group has previously
shown that CD33 antigen positive leukemic blasts from
patients with AML are sensitive to HuM195/rGel and
that F/T has a synergistic effect with low doses (1
nmol/L) of the immunotoxin [29]. We conﬁrmed those
results in our in vitro model: 10 nmol/L HuM195/rGel
followed by F/T eliminated 2 logs of leukemic blasts,
while HuM195/rGel alone did not have any toxic effect
on PBPCs. Less than half of the colony formation by
normal PBPCs was inhibited when cells were subjected
to F/T or HuM195/rGel followed by F/T. The inhibi-
tion rates did not differ between cells treated with F/T
and those treated with immunotoxin plus F/T, suggest-
ing that F/T was responsible for the toxicity on PBPCs
[30]. To adapt our study to the transplantation setting,
we upscaled the volume, cell density, and immunotoxin
concentration and used the exact procedure we use in
our transplantation unit to preserve the bone marrow.
Under these conditions, absolute CD34-positive cell
counts did not signiﬁcantly differ between treated and
untreated cells. Treatment with F/T or HuM195/rGel
followed by F/T inhibited colony formation moderately
although HuM195/rGel alone did not affect the forma-
tion of colonies by PBPCs.
Because leukemic clones hiding in the marrow of
patients in remission may contribute to relapse, [36]
several purging modalities have been developed.
Among the effective methods reported to date are
freezing procedure alone [37], cyclophosphamide de-
rivatives, MoAbs combined with complement, and im-
munotoxins.
The freezing procedure alone has been investi-
gated by Allieri et al. [37] to determine the intrinsic
AML-colony-forming unit (CFU) sensitivity to cryo-
preservation. Using 6 different freezing and thawing
techniques, one of which is very similar to ours with a
slight difference, they have been able to show that
normal CFU-granulocyte-macrophage (GM) has ex-
pressed similar cryopreservation sensitivity with a re-
covery rate of 48.44.6%, whereas the mean AML-
CFU recovery rate (9.23%) has been signiﬁcantly
low after freezing. Furthermore, the cloning efﬁciency
of AML-CFU after thaw has been signiﬁcantly de-
creased in 4 of 5 cases when compared with the fresh
samples. In contrast, the cloning efﬁciency has re-
mained the same in 3 of 4 cases of normal progenitors.
Such a selective toxicity resulting from cryopreserva-
tion has also been reported in a rat leukemia model
[38]. Our data conﬁrm previous observations that
AML-CFU is more affected by the F/T procedure
than is normal CFU-GM. As shown by Pagliaro et al.,
[29] the F/T procedure has a synergistic cytotoxic
effect with HuM195/rGel. From our results, we hy-
pothesize that, while HuM195/rGel is not cytotoxic at
low doses (up to 10 nmol/L) in CD33-positive cells, it
can inhibit the synthesis of proteins responsible for
survival during the F/T process.
Mafosfomide, a cyclophosphamide derivative, has
been used to remove leukemic cells from the autograft
but in vitro similar sensitivity of both leukemic and
normal progenitors to mafosfomide has limited its
application [39]. Douay et al. [40] have deﬁned a
residual amount of 5% CFU-GM as a safe limit for
bone marrow to repopulate after ex vivo mafosfomide
treatment. They have also determined that sensitivity
to mafosfomide depends on individual susceptibility of
the patients to the drug; therefore, it is recommended
that the dose should be adjusted on an individual basis.
In a clinical study reported by Rowley at al., [41] the
recovery rate of CFU-GM after 100 g/mL 4-hy-
droperoxycyclophosphamide has ranged from 0.07%
to 23%. It has been suggested that hematologic re-
covery may be reﬂected by the CFU-GM content of
the 4-hydroperoxycyclophosphamide purged au-
tografts.
Monoclonal antibodies anti-CD15 PM-81 and an-
ti-CD14 AML-2-23 binds to the blast cells of AML
patients highly and has been used in combination with
complement to purge bone marrow. This treatment
has caused a decrease in absolute CFU-GM numbers
by an average of 45%, but patients have ultimately
recovered despite delay in engraftment of normal my-
eloid cells [42]. Using another anti-CD33 immuno-
toxin, anti-MY9-blocked-ricin, an anti-CD33 anti-
body conjugated to a modiﬁed plant toxin ricin, Roy et
al. have demonstrated a 2-log elimination of primary
leukemic cells but a 70.7% inhibition in normal
CFU-GM [43].
Our results compare favorably with those purging
procedures found in the literature and suggest that
HuM195/rGel may be an effective and safe purging
reagent for patients with AML. Our in vitro data
warrant ex vivo studies in the clinical setting.
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